Safety and Tolerability of an Antibody Against Yellow Fever Virus (TY014) in Humans

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 6, 2018

Primary Completion Date

July 1, 2019

Study Completion Date

October 10, 2019

Conditions

Treatment of Acute Yellow Fever Virus Infection

Interventions

BIOLOGICAL

TY014

TY014 Injection, (100 mg/5 mL/Vial), Yellow Fever Virus (YFV) Monoclonal Antibody (mAb)

OTHER

0.9% Saline

Placebo

Trial Locations (1)

SingHealth Investigational Medicine Unit, Singapore

All Listed Sponsors

lead

Tysana Pte Ltd

INDUSTRY

NCT03776786 - Safety and Tolerability of an Antibody Against Yellow Fever Virus (TY014) in Humans | Biotech Hunter | Biotech Hunter